ER-positive/HER2-negative breast cancer
Conditions
Interventions
observation group:None
Sponsors
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 or older, female; 2. Pathologically confirmed invasive breast cancer through core needle biopsy (including invasive ductal carcinoma, invasive lobular carcinoma, and other special types); 3. Received a full course of neoadjuvant chemotherapy (= 4 cycles of an anthracycline- and/or taxane-based regimen); 4. Underwent modified radical mastectomy or breast-conserving surgery with axillary lymph node dissection (ALND) after neoadjuvant chemotherapy; 5. Have a complete surgical pathology report, including total number of axillary lymph nodes examined, number of metastatic lymph nodes, MP grading or residual cancer burden (RCB) assessment, ypN staging; 6. Have Ki-67 immunohistochemistry results before neoadjuvant treatment.
Exclusion criteria
Exclusion criteria: 1. Inflammatory breast cancer (T4d); 2. Newly diagnosed stage IV (M1) breast cancer; 3. Patients who had a sentinel lymph node biopsy (SLNB) before neoadjuvant chemotherapy but did not complete ALND afterwards; 4. Patients who received radiotherapy during neoadjuvant chemotherapy; 5. Patients whose preoperative biopsy showed ER- or Her- tumors; 6. Synchronous bilateral breast cancer; 7. History of previous malignancy; 8. Key variables (total lymph nodes, Ki-67, MP grade, ypN) missing and cannot be supplemented.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total pathological complete response, pCR;total lymph node yield, TLNY; | — |
Countries
China
Contacts
Public ContactWenjie Lv
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed